• 1
    Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation. 2010;121:e46e215.
  • 2
    Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing Committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154e235.
  • 3
    Sole MJ, Jeejeebhoy KN. Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure. Curr Opin Clin Nutr Metab Care. 2000;3:417424.
  • 4
    Soukoulis V, Dihu JB, Sole M, et al. Micronutrient deficiencies: an unmet need in heart failure. J Am Coll Cardiol. 2009;54:16601673.
  • 5
    Schaffer SW, Kramer J, Chovan JP. Regulation of calcium homeostasis in the heart by taurine. Fed Proc. 1980;39:26912694.
  • 6
    Beyranvand MR, Kadkhodai Khalafi M, Roshan VD, et al. Effect of taurine supplementation on exercise capacity of patients with heart failure. J Cardiol. 2011;57:333337.
  • 7
    Jeejeebhoy F, Keith M, Freeman M, et al. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J. 2002;143:10921100.
  • 8
    Azuma J, Hasegawa H, Sawamura A, et al. Taurine for treatment of congestive heart failure. Int J Cardiol. 1982;2:303304.
  • 9
    Azuma J, Sawamura A, Awata N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J. 1992;56:9599.
  • 10
    Ito T, Kimura Y, Uozumi Y, et al. Taurine depletion caused by knocking out the taurine transporter gene leads to cardiomyopathy with cardiac atrophy. J Mol Cell Cardiol. 2008;44:927937.
  • 11
    Littarru GP, Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol. 2007;37:3137.
  • 12
    Folkers K, Langsjoen P, Langsjoen PH. Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant. Biochem Biophys Res Commun. 1992;182:247253.
  • 13
    Strey CH, Young JM, Molyneux SL, et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis. 2005;179:201206.
  • 14
    Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci U S A. 1985;82:901904.
  • 15
    Molyneux SL, Florkowski CM, George PM, et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol. 2008;52:14351441.
  • 16
    Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc Natl Acad Sci U S A. 1985;82:42404244.
  • 17
    Munkholm H, Hansen HH, Rasmussen K. Coenzyme Q10 treatment in serious heart failure. Biofactors. 1999;9:285289.
  • 18
    Keogh A, Fenton S, Leslie C, et al. Randomised double-blind, placebo-controlled trial of coenzyme Q, therapy in class II and III systolic heart failure. Heart Lung Circ. 2003;12:135141.
  • 19
    Belardinelli R, Mucaj A, Lacalaprice F, et al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J. 2006;27:26752681.
  • 20
    Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin Investig. 1993;71:S134S136.
  • 21
    Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol. 1999;33:15491552.
  • 22
    Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med. 2000;132:636640.
  • 23
    Sander S, Coleman CI, Patel AA, et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail. 2006;12:464472.
  • 24
    Rosenfeldt FL, Haas SJ, Krum H, et al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens. 2007;21:297306.
  • 25
    Arsenian MA. Carnitine and its derivatives in cardiovascular disease. Prog Cardiovasc Dis. 1997;40:265286.
  • 26
    Schonekess BO, Allard MF, Lopaschuk GD. Propionyl l-carnitine improvement of hypertrophied heart function is accompanied by an increase in carbohydrate oxidation. Circ Res. 1995;77:726734.
  • 27
    Masumura Y, Kobayashi A, Yamazaki N. Myocardial free carnitine and fatty acylcarnitine levels in patients with chronic heart failure. Jpn Circ J. 1990;54:14711476.
  • 28
    Serati AR, Motamedi MR, Emami S, et al. l-carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms. Cardiology. 2010;116:178182.
  • 29
    Iliceto S, Scrutinio D, Bruzzi P, et al. Effects of l-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the l-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol. 1995;26:380387.
  • 30
    Rizos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and l-carnitine administration. Am Heart J. 2000;139:S120S123.
  • 31
    Study on propionyl-l-carnitine in chronic heart failure. Eur Heart J. 1999;20:7076.
  • 32
    Seligmann H, Halkin H, Rauchfleisch S, et al. Thiamine deficiency in patients with congestive heart failure receiving long-term furosemide therapy: a pilot study. Am J Med. 1991;91:151155.
  • 33
    Zenuk C, Healey J, Donnelly J, et al. Thiamine deficiency in congestive heart failure patients receiving long term furosemide therapy. Can J Clin Pharmacol. 2003;10:184188.
  • 34
    Brady JA, Rock CL, Horneffer MR. Thiamin status, diuretic medications, and the management of congestive heart failure. J Am Diet Assoc. 1995;95:541544.
  • 35
    Hanninen SA, Darling PB, Sole MJ, et al. The prevalence of thiamin deficiency in hospitalized patients with congestive heart failure. J Am Coll Cardiol. 2006;47:354361.
  • 36
    Kwok T, Falconer-Smith JF, Potter JF, Ives DR. Thiamine status of elderly patients with cardiac failure. Age Ageing. 1992;21:6771.
  • 37
    Pfitzenmeyer P, Guilland JC, d’Athis P, et al. Thiamine status of elderly patients with cardiac failure including the effects of supplementation. Int J Vitam Nutr Res. 1994;64:113118.
  • 38
    Shimon I, Almog S, Vered Z, et al. Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapy. Am J Med. 1995;98:485490.
  • 39
    Da Cunha S, Albanesi Filho FM, Da Cunha Bastos VL, et al. Thiamin, selenium, and copper levels in patients with idiopathic dilated cardiomyopathy taking diuretics. Arq Bras Cardiol. 2002;79:454465.
  • 40
    Rocha RM, Silva GV, De Albuquerque DC, et al. Influence of spironolactone therapy on thiamine blood levels in patients with heart failure. Arq Bras Cardiol. 2008;90:324328.
  • 41
    Smithline HA. Thiamine for the treatment of acute decompensated heart failure. Am J Emerg Med. 2007;25:124126.
  • 42
    Keith ME, Walsh NA, Darling PB, et al. B-vitamin deficiency in hospitalized patients with heart failure. J Am Diet Assoc. 2009;109:14061410.
  • 43
    Herrmann M, Kindermann I, Muller S, et al. Relationship of plasma homocysteine with the severity of chronic heart failure. Clin Chem. 2005;51:15121515.
  • 44
    Vasan RS, Beiser A, D’Agostino RB, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA. 2003;289:12511257.
  • 45
    Refsum H, Smith AD, Ueland PM, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem. 2004;50:332.
  • 46
    Stanger O, Weger M. Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. Clin Chem Lab Med. 2003;41:14441454.
  • 47
    Herrmann W, Herrmann M, Obeid R. [Hyperhomocysteinemia and B-vitamin deficiency Current clinical aspects]. Med Monatsschr Pharm. 2006;29:291302.
  • 48
    Herrmann M, Stanger O, Paulweber B, et al. Effect of folate supplementation on N-terminal pro-brain natriuretic peptide. Int J Cardiol. 2007;118:267269.
  • 49
    Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol. 2009;54:585594.
  • 50
    London B, Albert C, Anderson ME, et al. Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office Of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop. Circulation. 2007;116:e320e335.
  • 51
    Leaf A, Weber PC. Cardiovascular effects of n-3 fatty acids. N Engl J Med. 1988;318:549557.
  • 52
    Lee JH, O’Keefe JH, Lavie CJ, et al. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc. 2008;83:324332.
  • 53
    Mehra MR, Lavie CJ, Ventura HO, Milani RV. Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure. J Heart Lung Transplant. 2006;25:834838.
  • 54
    Wang C, Harris WS, Chung M, et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr. 2006;84:517.
  • 55
    Tavazzi L, Tognoni G, Franzosi MG, et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail. 2004;6:635641.
  • 56
    Mozaffarian D, Bryson CL, Lemaitre RN, et al. Fish intake and risk of incident heart failure. J Am Coll Cardiol. 2005;45:20152021.
  • 57
    Lavie CJ, O’Keefe JH, Milani RV, et al. New data on the clinical impact of exercise training, fish oils, and statins in heart failure. Phys Sportsmed. 2009;37:2228.
  • 58
    Yamagishi K, Nettleton JA, Folsom AR. Plasma fatty acid composition and incident heart failure in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2008;156:965974.
  • 59
    Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:12231230.
  • 60
    Freeman LM, Rush JE, Kehayias JJ, et al. Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure. J Vet Intern Med. 1998;12:440448.
  • 61
    Yamagishi K, Iso H, Date C, et al. Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women the JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk) Study. J Am Coll Cardiol. 2008;52:988996.
  • 62
    Fonarow GC. Statins and n-3 fatty acid supplementation in heart failure. Lancet. 2008;372:11951196.
  • 63
    Lee JH, O’Keefe JH, Bell D, et al. Vitamin D deficiency: an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol. 2008;52:19491956.
  • 64
    Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol. 2006;92:3948.
  • 65
    Schierbeck LL, Jensen TS, Bang U, et al. Parathyroid hormone and vitamin D – markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail. 2011;13:626632.